Alle episoder

Join rheumatology experts Dr. John J. Cush and Dr. Arthur Kavanaugh for the EULAR Rheumatology RoundUp — a dynamic, fast-paced discussion capturing th...

Trends and Innovations from Barcelona (6.20.2025) AI Advances axSpA Diagnosis with Multimodal MRI IL-17 Inhibitors in Psoriatic Arthritis IL-17 Inh...

Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life Spondyloarthritis Panel: Eular 2025

Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from E...

Digital Behavioural Therapy for Persistent Pain in Axial Spondyloarthritis There's an App for That (and it works): the AXIA RCT

Eular 2025 PsA Topic Panel Assessment of Peripheral Arthritis in Spondyloarthritis IL-17 inhibitors - Novel Drugs IL17 inhibitors - Long-term Exten...

Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in...

Efficacy and Safety of Xeligekimab in AS Sonelokimab in PsA Seronegative Arthritis Breakthroughs Novel Therapies in Axial Spondyloarthritis

JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral ...

Who/When to Treat Clinically Suspect Arthralgia Thoughtful, Effective RA Care Should be Guided by Need —Not Age The Impact of Biologics on Methotrex...

Efficacy and Safety of Xeligekimab in AS Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-...

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Biologic Swi...

EULAR 2025 - Day 1 podcasts Sonelokimab in PsA Seronegative Arthritis Breakthroughs Using Combination csDMARDs in PsA Deucravacitinib's Place in t...

Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact GLP 1 Receptor...

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Emerging The...

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key...

Deucravacitinib's Place in the PsA Treatment Algorithm? Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Earl...

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key ...

Seronegative Arthritis Breakthroughs Jokes Aside: The Impact of Laughter in RA The Impact of Biologics on Methotrexate Adherence Thoughtful, Effect...

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the first day of EULAR 2025. Join us live as we break down the key ...

Efficacy and Safety of Xeligekimab in AS Who/When to Treat Clinically Suspect Arthralgia

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

New Steroid Rules for Lupus - Dr. Michelle Petri Management of CKD in Lupus Nephritis - Dr. HJ Anders HCQ Levels and Adherence - Dr. Nathalie Costed...

In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycop...

- QD286: Early Lupus (Dr. Jack Cush) https://youtu.be/zzpC397FhZ0 - QD287: A Different Strategy to Tackle Non-adherence (Dr. Megan Clowse)  https://y...

- QD282: SLE Get Ready (Dr. Jack Cush) https://youtu.be/UWNAxiuwZro - QD283: Rhupus  (Dr. Jack Cush) https://youtu.be/OJUfylWJf4c - QD284: The Dilem...

- QD279: Hyperpigmentation in Lupus (Dr. Jack Cush) https://youtu.be/xA9nvuadhCg - QD280: Polar Opposite Approaches for Lupus (Dr. Eric Dein) https:/...